- Home
- CDXS vs ACIU Comparison
CDXS vs ACIU Comparison
Compare CDXS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDXS | ACIU |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 288.0M |
| IPO Year | 2008 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CDXS | ACIU |
|---|---|---|
| Price | $2.47 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 255.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | $7.73 | $706.75 |
| Revenue Next Year | $14.24 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $1.60 |
| 52 Week High | $3.87 | $4.00 |
Technical Indicators
Market Signals| Indicator | CDXS | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 46.57 |
| Support Level | $2.40 | $2.58 |
| Resistance Level | $2.67 | $2.99 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 21.43 | 37.00 |
Price Performance
Historical ComparisonAbout CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.